Clinical trials: Plaque Psoriasis.
Plaque Psoriasis
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
- Trial name
- NCT05739435
- Testing
- envudeucitinib
- Where
- 38 sites in United States, Canada
- Volunteers
- 165 people
- Sponsor
- Alumis Inc
Psoriasis
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab…
- Trial name
- NCT00195676
- Testing
- adalimumab
- Where
- 104 sites in United States, Austria and 8 more
- Volunteers
- 1,469 people
- Sponsor
- Abbott
Psoriasis
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis.
- Trial name
- NCT05642182
- Testing
- SFA002
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- SFA Therapeutics
Moderate to Severe Plaque-type Psoriasis
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
This was an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab.
- Trial name
- NCT01544595
- Testing
- Secukinumab (AIN457)
- Where
- 182 sites in United States, Argentina and 24 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris
A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis
The primary objective of the study is to assess the tolerability and efficacy of a 0.10% or 0.05% PTH (1-34) parathyroid hormone peptide gel in the treatment of mild to moderate plaque psoriasis in comparison to treatment with…
- Trial name
- NCT00593177
- Where
- 4 sites in United States
- Volunteers
- 61 people
- Sponsor
- Manhattan Pharmaceuticals
Plaque Psoriasis
Treatment of Moderate to Severe Plaque Psoriasis
To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis, as well as the PK and PD characteristics of multiple doses
- Trial name
- NCT06542614
- Testing
- TQH3906 capsules
- Where
- 35 sites in China
- Volunteers
- 209 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection…
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT04018599
- Testing
- 40 mg MSB11022
- Where
- 2 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Psoriasis
Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study
The objectives of this study are to evaluate the efficacy and safety of two dosing regimens of desoximetasone 0.05% and 0.25% topical sprays as compared to a vehicle spray in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01018134
- Testing
- Desoximetasone 0.05% once daily, Desoximetasone 0.05% twice daily, Desoximetasone 0.25% once daily
- Where
- 7 sites in United States
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Trial name
- POETYK-PSO-1 (NCT03624127)
- Testing
- BMS-986165, Apremilast
- Where
- 165 sites in United States, Canada and 9 more
- Volunteers
- 666 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate…
- Trial name
- NCT04761627
- Testing
- Ustekinumab, ABP 654
- Where
- 88 sites in United States, Canada and 6 more
- Volunteers
- 494 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Psoriatic Arthritis
A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.
The purpose of this non-interventional study is to evaluate the efficacy of etanercept during routine clinical use over a maximum of 12 months in patients with rheumatoid arthritis (RA), psoriatic arthritis(PsA), axial…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Plaque Psoriasis
- Trial name
- ADEQUATE (NCT02486302)
- Testing
- Etanercept
- Where
- 180 sites in Germany
- Volunteers
- 1,534 people
- Sponsor
- Pfizer
Parapsoriasis
Natural Gels for Treatment of Plaque Psoriasis
The aim of the study is to evaluate the safety and the therapeutic activity of the combination of Natural Gel combination and hair mask of plant origin in patients with mild to moderate plaque psoriasis.
- Trial name
- NCT02330237
- Testing
- natural gels
- Where
- Israel
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Secret of Youth
Psoriasis
A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis
A multi-center, open-label study that will evaluate the safety/tolerability and pharmacodynamics as well as the pharmacokinetic profile (sub-population analysis), in 50 evaluable adolescents 12 to < 17 years of age.
- Trial name
- NCT02970331
- Testing
- pefcalcitol ointment, 0.005%
- Sponsor
- Maruho Co., Ltd.
Moderate to Severe Chronic Plaque Psoriasis
Post Marketing Observational Study on Venezuelan Patients With Psoriasis
The aim of this study is to obtain Venezuelan data of clinical effectiveness, impact in the HRQoL, work productivity and activity impairment in patients with psoriasis using adalimumab.
- Trial name
- NCT01758705
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Plaque
A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.
- Trial name
- NCT04911751
- Testing
- KBL697
- Where
- 10 sites in United States, Australia
- Volunteers
- 80 people
- Sponsor
- KoBioLabs
Psoriasis
A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of mild-to-moderate plaque psoriasis.
- Trial name
- NCT06926582
- Testing
- HS-10374 6mg tablets
- Where
- China
- Volunteers
- 305 people
- Sponsor
- Hansoh BioMedical R&D Company
Psoriasis
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque…
- Trial name
- PSOR-001 (NCT00604682)
- Testing
- CC10004
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Amgen
Plaque Psoriasis
ACT-128800 in Psoriasis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT00852670
- Testing
- ACT-128800
- Where
- 14 sites in Austria, France and 3 more
- Volunteers
- 66 people
- Sponsor
- Actelion
Plaque Psoriasis
Understanding Participation Habits Among Plaque Psoriasis Patients
The study intends to investigate the personal experiences of plaque psoriasis patients who take part in a separate clinical study including a specific medication intervention.
- Trial name
- NCT06338358
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Nail Psoriasis, Plaque Psoriasis
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
This study is being conducted to assess the safety and efficacy of adalimumab in participants with nail psoriasis.
- Trial name
- NCT02016482
- Testing
- Adalimumab
- Volunteers
- 217 people
- Sponsor
- AbbVie